Compare NATL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | RCKT |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 534.2M |
| IPO Year | 2023 | N/A |
| Metric | NATL | RCKT |
|---|---|---|
| Price | $43.78 | $3.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $45.60 | $29.73 |
| AVG Volume (30 Days) | 1.2M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $4.24 | $51.17 |
| P/E Ratio | $20.44 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $22.30 | $2.19 |
| 52 Week High | $48.50 | $8.26 |
| Indicator | NATL | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 38.79 |
| Support Level | $42.03 | $2.99 |
| Resistance Level | $48.50 | $4.08 |
| Average True Range (ATR) | 0.96 | 0.37 |
| MACD | -0.18 | -0.16 |
| Stochastic Oscillator | 61.62 | 9.66 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.